Integrated PERSEVERE and endothelial biomarker risk model predicts death and persistent MODS in pediatric septic shock: a secondary analysis of a prospective observational study
Authors:
Open Access
- 11 July 2022
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-9
Abstract
Background: Multiple organ dysfunction syndrome (MODS) is a critical driver of sepsis morbidity and mortality in children. Early identification of those at risk of death and persistent organ dysfunctions is necessary to enrich patients for future trials of sepsis therapeutics. Here, we sought to integrate endothelial and PERSEVERE biomarkers to estimate the composite risk of death or organ dysfunctions on day 7 of septic shock. Methods: We measured endothelial dysfunction markers from day 1 serum among those with existing PERSEVERE data. TreeNet® classification model was derived incorporating 22 clinical and biological variables to estimate risk. Based on relative variable importance, a simplified 6-biomarker model was developed thereafter. Results: Among 502 patients, 49 patients died before day 7 and 124 patients had persistence of MODS on day 7 of septic shock. Area under the receiver operator characteristic curve (AUROC) for the newly derived PERSEVEREnce model to predict death or day 7 MODS was 0.93 (0.91–0.95) with a summary AUROC of 0.80 (0.76–0.84) upon tenfold cross-validation. The simplified model, based on IL-8, HSP70, ICAM-1, Angpt2/Tie2, Angpt2/Angpt1, and Thrombomodulin, performed similarly. Interaction between variables—ICAM-1 with IL-8 and Thrombomodulin with Angpt2/Angpt1—contributed to the models’ predictive capabilities. Model performance varied when estimating risk of individual organ dysfunctions with AUROCS ranging from 0.91 to 0.97 and 0.68 to 0.89 in training and test sets, respectively. Conclusions: The newly derived PERSEVEREnce biomarker model reliably estimates risk of death or persistent organ dysfunctions on day 7 of septic shock. If validated, this tool can be used for prognostic enrichment in future pediatric trials of sepsis therapeutics. GraphicalKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK119463)
- National Institute of Child Health and Human Development (R01HL161362, RL1HD107776, R00HD099387)
- National Heart, Lung, and Blood Institute (K23HL151897)
- National Institute of General Medical Sciences (R35 GM126943, R35 GM126943)
This publication has 30 references indexed in Scilit:
- Pediatric Sepsis Biomarker Risk Model-II: Redefining the Pediatric Sepsis Biomarker Risk Model With Septic Shock PhenotypeCritical Care Medicine, 2016
- Global Epidemiology of Pediatric Severe Sepsis: The Sepsis Prevalence, Outcomes, and Therapies StudyAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Developing a Clinically Feasible Personalized Medicine Approach to Pediatric Septic ShockAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Why have clinical trials in sepsis failed?Trends in Molecular Medicine, 2014
- The pediatric sepsis biomarker risk modelCritical Care, 2012
- Clinical utility of biomarkers of endothelial activation in sepsis-a systematic reviewCritical Care, 2012
- Validation of a gene expression-based subclassification strategy for pediatric septic shock*Critical Care Medicine, 2011
- Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe SepsisJAMA, 2010
- International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*Pediatric Critical Care Medicine, 2005
- The pediatric risk of mortality III— Acute physiology score (PRISM III-APS): A method of assessing physiologic instability for pediatric intensive care unit patientsThe Journal of Pediatrics, 1997